EnteroBiotix is on a mission to master the gut microbiome to develop pioneering therapeutics that restore health by treating and preventing disease.
EnteroBiotix is a leading microbiome therapeutics company. Its vision is to transform the standard of care for patients suffering from substantial unmet clinical needs through microbiome modulating therapeutics. EnteroBiotix’s products hold the promise to significantly improve patient outcomes by alleviating symptoms, eliminating infection, and ultimately saving lives.
EnteroBiotix was founded in 2017 by Dr James McIlroy. His vision was ignited when he recognised the therapeutic potential of the microbiome. Since then, the company has established a value-aligned multi-disciplinary team with substantial experience in bringing products through the full development pathway, from the lab to successful clinical studies.
Following on from an oversubscribed investment round of £2 million in 2019, EnteroBiotix has gone on to raise over £15.5 million in Series A financing in 2021. SIS Ventures was delighted to invest in both rounds.
The funds support EnteroBiotix to further advance its microbiome drug pipeline as well as underpin its product development and manufacturing capabilities. In addition, it is helping the company grow its headcount to around 50 to drive its mission of addressing diseases by enhancing the diversity of the microbiome for a healthier life. With its product portfolio having the potential to be applied across multiple disease areas, the potential impact on lives is significant.
With the human gut microbiome having the potential to change modern medicine, SIS Ventures is delighted to be supporting EnteroBiotix as it builds a sustainable pharmaceutical company.
“This successful financing round is a strong endorsement of our pioneering microbiome approach. It gives significant momentum to our mission to transform the lives of patients through novel orally delivered medicinal products that enhance the gut microbiome. We are determined to change the standard of care for patients battling debilitating diseases associated with the microbiome.”
Dr James McIlroy, CEO, EnteroBiotix
Beta Bugs secures £1.72m to scale up sustainable insect farmingRead more about Beta Bugs secures £1.72m to scale up sustainable insect farming
Microplate Dx secures £2.5m to develop rapid antibiotic testing technologyRead more about Microplate Dx secures £2.5m to develop rapid antibiotic testing technology
SIS Ventures joins EIS AssociationRead more about SIS Ventures joins EIS Association